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Background: Cardiac resynchronization therapy (CRT) is known to be effective for patients with heart
failure. However, despite data suggesting that routine atrioventricular (AV) and interventricular (VV)
delay optimization may play signiﬁcant roles in CRT, there is no standard on how and when the CRT
device should be optimized. The aim of this study was to characterize the current practice of CRT
optimization in Japan.
Methods: A survey was conducted to collect information on the procedural aspects of AV and VV delay
optimization. The key survey items concerned what method is used for optimization, when optimization
is performed, and what factors limit repetitive optimization.
Results: Fifty-two physicians participated in the survey. Echocardiography was the chosen method for
assessing AV and VV delays by 79.6% and 65.3% of physicians, respectively, and routine optimization was
performed by 28.3%. The majority optimized the settings only once at pre-hospital discharge or on an
“as-needed” basis. The factors limiting repeated optimization were the lack of available time (71.2%),
qualiﬁed staff (53.8%), and reliable methods (55.8%).
Conclusions: Repetitive CRT optimization is infrequently performed in Japan. Lack of time, human
resource, and reliable methods were the major factors affecting the number of routine CRT optimization.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
It is widely accepted that treatment with cardiac resynchroni-
zation therapy (CRT) is effective for patients with advanced heart
failure, and this is supported by a series of randomized, controlled
clinical trials [1–6]. The underlying mechanism of this therapy is to
improve the contractile movement of the heart by adjusting the
interventricular (VV) and intraventricular delays. This is done by
correcting electrical and mechanical dyssynchrony through an
optimally timed stimulation of the right ventricle (RV) and the
left ventricle (LV). The clinical beneﬁts conferred by CRT include
improvements in the quality of life, New York Heart Association
functional classiﬁcation, and cardiac structure and function, as
well as reduction in morbidity and mortality [1–8]. Although this
therapy has been proven effective in numerous clinical trials,
reports show that up to one-third of patients (the so-called
nonresponders) do not receive the full clinical beneﬁt of CRTt Rhythm Society. Published by Els
+81 3 6430 7140.
oi).[9,10]. The causes for this nonresponsiveness of patients are still
unclear; however, inadequate patient selection, suboptimal lead
position, and device programming may inﬂuence the outcome.
Reports show relatively equal responder rates between a Japanese
cohort [11] and patients from other countries [12]. This raised the
question of how daily CRT management is being practiced
in Japan.
Heart failure is a complex disease and the status of each patient is
highly heterogeneous; therefore, nominal manufacturer-delivered
device settings may not be optimal for all patients who receive CRT
implantation. A growing body of evidence suggests hemodynamic
and clinical status beneﬁts associated with optimization of atrioven-
tricular (AV) and VV delays [13–16]. However, alteration of the atrial
and ventricular morphologies over time because of reverse remodel-
ing may also inﬂuence these parameters, which may have been
optimal at the time of implantation [17,18]. The optimizationmethods
preferred by Japanese physicians and the duration between repeated
optimizations are unknown, and there is no general consensus among
physicians about the need for routine optimization. The goal of this
study was to collect information on the current status of CRT device
optimization in Japan.evier B.V. All rights reserved.
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A questionnaire survey was conducted to collect information
on the practice of CRT optimization of physicians who implant CRT
devices in Japan. The collected data were focused on the method
used to optimize AV and VV delays, the time required for the
optimization, and the frequency of repetitive optimization during
follow-up visits. The English translation of the questionnaire is
shown in Table 1. Physicians who use device functions such as
QuickOpt (St. Jude Medical, Minneapolis, MN, USA) [19], which
monitor intracardiac electrograms, to optimize CRT parameters
were instructed to mark “Other” and specify this on the answer
sheets. The participating physicians were selected from centers
that perform frequent CRT device implantations, nominally more
than 10 procedures per year. Additional care was taken to mini-
mize regional variance by selecting centers from each geographical
area in Japan. Owing to the foreseen difﬁculty, centers in north-
eastern Japan were excluded because that region was severely
affected by the March 11, 2011, earthquake. Descriptive statistics
were performed for categorical variables. Statistical signiﬁcance
was not analyzed owing to the nature of this study.Table 1
Survey questionnaire.
Please answer the following questions on the basis of your experiences with CRT opt
Questions Answ
Which method is being used the most to optimize A-V delay? □Echo
□Inva
□Imp
□Elec
□Othe
□Do n
Which method is being used the most to optimize V-V delay? □ Ech
□ Inv
□ Oth
□ Do
How long does it usually take you to complete optimization? Both
A-V o
V-V o
How often do you optimize A-V and/or V-V delays after implantation? □ Eve
□ Eve
□ Oth
What percentage of your patients are optimized during each follow-up visit? Visit
Impla
Pre-h
3 mo
6 mo
12 m
Select the factor(s) limiting the performance of
optimization, if any. (Multiple answers allowed.)
□ Tim
□ Lac
□ Hig
□ Oth3. Results
The questionnaires were retrieved from all 52 physicians from
47 centers in Japan, who were initially selected for participation
between May 11 and July 25, 2011. Because the number of annual
CRT implantation procedures was part of the center selection
criteria, there was a trend of including centers in the metropolitan
area; nevertheless, the overall distribution of the centers was well
balanced throughout all geographical regions of Japan. No centers
from northeastern Japan and the Shikoku Island area were
enrolled for administrative reasons. As there are approximately
350 accredited CRT implanting centers in Japan, the survey
covered 410% of the applicable sites. These centers implanted
910 of 2864 CRT devices in the year 2010, which accounted for
31.8% of all CRT implantations performed in the country.3.1. Methods used to optimize AV and VV delays
The frequency distribution of the methods used to optimize AV
and VV delays are shown in Fig. 1. Data from 49 (94.2%) physiciansimization
ers
cardiography (Please select one of the following options.)
□ Iterative method
□ Ritter's method
□ Simpliﬁed (Meluzin) mitral inﬂow method
□ Mitral inﬂow VTI
□ Diastolic mitral regurgitation (Ishikawa) method
□ Other (Specify:)
sive LV dP/dtmax
edance cardiography (ICG)
trocardiogram
r (Specify:)
ot optimize
ocardiography (Please select one of the following options)
□ LV dP/dtmax
□ LV outﬂow tract VTI
□ Tissue Doppler imaging
□ Other (Specify:)
asive LV dP/dtmax
er (Specify:)
not optimize
A-V and V-V: hour(s) and minutes
nly: hour(s) and minutes
nly: hour(s) and minutes
ry month □ Every 2 months
ry 3 months □ Every 6 months
er (Specify:)
A-V and V-V A-V only V-V only Not optimized
ntation % % % %
ospital discharge % % % %
nths after implantation % % % %
nths after implantation % % % %
onths after implantation % % % %
e constraint
k of qualiﬁed staff
hly reliable method not being established
er (Specify:)
Fig. 1. Proportion of methods used to assess AV and VV delays. Echo, echocardio-
graphy; LV dP/dtmax, maximum rate of left ventricular pressure increase; BP, blood
pressure; and RV cath, right ventricular catheterization.
Table 2
Time required for optimization.
Optimized delays (no. of valid responses)
AV only (n¼30) VV only (n¼28) AV and VV (n¼39)
Mean7SD (min) 1879 20712 32715
Range (min) 5–40 5–60 10–60
SD, standard deviation.
Fig. 2. Proportion of physicians who perform routine device optimization.
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physicians did not provide an answer or multiple selections were
chosen, which was not allowed.
Most of the responding physicians (79.6%) used echocardio-
graphy as the method of choice for optimizing AV delay. The less
frequently used methods were surface electrocardiogram (ECG)
(4.1%), blood pressure (BP) monitoring (4.1%), and invasive LV dP/
dtmax measurement (2.0%). The remaining 10.2% responded that
they did not perform AV optimization. A similar trend was also
observed for VV delay optimization, with a slightly higher variance
in methods among physicians. Echocardiography was used by
65.3% of physicians, ECG by 6.1%, BP by 8.2%, LV dP/dtmax by
4.1%, and RV catheterization by 2.0%. The VV delay was not
optimized by 14.3% of physicians, which was a slightly higher
portion compared with the AV delay.
Thirty-ﬁve of 39 (89.7%) physicians who used echocardiogra-
phy to optimize AV delay employed pulsed Doppler of LV diastolic
ﬁlling to determine the optimal device parameters. Measurement
of the LV outﬂow tract velocity–time integral (VTI) was the
preferred method for selecting the optimal VV parameters by 24
of 32 (75.0%) physicians who used echocardiography for VV
optimization.
None of the physicians chose device-monitored intracardiac
electrograms, such as QuickOpt, as their most frequently used
method for CRT optimization.3.2. Time required for optimization
The time necessary to optimize AV and/or VV delays is shown
in Table 2. To optimize either the AV or the VV delay, the
responding physicians spent an average of 20 min, whereas more
than 30 min was required to optimize both delays. If the data were
limited to echocardiographic evaluation only, the time necessaryto optimize AV, VV, and AV and VV delays were 1779, 1779, and
29714 min, respectively.
3.3. Frequency of optimization after implantation
The proportion of physicians who perform optimization reg-
ularly is shown in Fig. 2. Most of them (71.7%) optimized the
device settings only once at pre-hospital discharge or on an “as-
needed” basis, such as when symptoms worsened and/or when
patients did not respond to CRT therapy. These cases are referred
to as “nonroutine” optimization in the ﬁgure. Only a few of the
physicians performed optimization at regularly scheduled inter-
vals. The percentage of physicians who optimized the devices
every 3 and 6 months was 8.7% and 13.0%, respectively, and 6.5%
speciﬁed other time intervals.
The proportion of patients who undergo device optimization at
each follow-up visit is shown in Fig. 3. More than half of the
physicians optimized the device in all (100%) of their patients at
pre-hospital discharge. In contrast, most of the physicians did not
perform optimization in any of their patients during implantation
and at the follow-up visits.
3.4. Obstacles to device optimization
The physicians were questioned about what may be limiting
them from performing CRT optimization. They were allowed to
report multiple reasons, and the most commonly reported factor
was time constraint (71.2%). The other major factors were the lack
of qualiﬁed staff (53.8%) and unreliable optimization methods
(55.8%).4. Discussion
This report describes the daily practices with regard to AV and VV
delay optimization by physicians managing CRT patients in Japan.
Most of the physicians responded that they only optimize AV and VV
delays once at pre-hospital discharge and very few physicians
regularly optimized AV and/or VV delay settings thereafter. A low
rate of routine CRT device optimization has also been reported in
physician surveys obtained from other countries [20]. The effective-
ness of repetitive optimization is currently unclear, and it is presently
unknown whether the device parameters optimized at pre-hospital
discharge would remain optimal in the long term. The lack of time
and human resources were the major obstacles preventing frequent
optimization. The fact that there have been no established, reliable
standardized methods for optimizing CRT may be another factor
inﬂuencing the frequency of optimization. The physicians' perception
toward optimization with unreliable methods may reﬂect upon their
Fig. 3. Percentage of physicians optimizing certain proportion of patients for (A) AV and (B) VV delays at implantation (Im); pre-hospital discharge (PHD); and 3, 6, and 12 months.
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reducing the rate of repetitive optimization. The correlation between
a standardized optimization method and CRT responsiveness is yet to
be elucidated.
Although echocardiographic evaluation can be time consuming
and costly, this method is being used most frequently by Japanese
physicians when performing device optimization, similar to pre-
vious reports from other countries [20]. To reduce the increasing
burden of CRT device follow-up and to allow timely optimization
of these devices, optimization algorithms such as QuickOpt [19]
and SmartDelay (Boston Scientiﬁc, Natick, MA, USA) [21,22] have
been developed. These features monitor the heart conditions of
patients to calculate the most optimal AV and/or VV delays and
assist the physicians in reprogramming the devices during follow-
ups. Although none of the physicians chose either of those device
algorithms as their most frequently used method for optimizing
AV and/or VV delays, 2 of them stated that they do incorporate
device-suggested values as a reference. One limitation of these
algorithms is that they are not automated and still require
compliance with routine in-ofﬁce reprogramming. Another newly
developed algorithm, SonR (Sorin CRM SAS, Clamart, France) [23–
25], performs weekly automated optimization of the AV delay, but
the patients need to visit the clinic in order to have the VV delay
optimized. The requirement for multiple clinic visits and for the
manual optimization of the CRT conﬁguration by methods such as
echocardiography and device functionalities may be burdensome
to both patients and physicians. A fully automated and self-
reprogramming CRT optimization algorithm may reduce the bur-
den of optimization by minimizing the need for routine ofﬁce
visits and may prove beneﬁcial by allowing continuous adjustment
of device settings according to the most recent clinical status of
the patient. The efﬁcacy of repetitive CRT optimization is yet to be
elucidated, as intermittent reprogramming of the device during
each follow-up visit may not reﬂect the continuous change of
biological status in patients. However, landmark trials such as
MIRACLE [2], COMPANION [5], and CARE-HF [6] required the AV
and VV delays to be optimized at pre-hospital discharge and
during each follow-up visits. A new algorithm that continuously
monitors cardiac conduction and automatically reprograms AV
and VV delays is being evaluated [26]. With this new technology, it
may be possible to constantly update the CRT parameters to reﬂect
the most recent cardiac condition. As the effectiveness of AV andVV delay optimization is still under discussion, the next goal
would be to clarify the correlation between the patient outcome
and the optimal CRT in the long term.
4.1. Limitations
Owing to the design of this surveillance study, the information
collected from each physician is subjective in nature, and the
number of physicians who participated in the survey was rela-
tively small. On planning this study, special care was taken to
broadly collect data, including most geographical areas of Japan, in
order to obtain generalized results. As it is difﬁcult to standardize
the deﬁnition of “responders” between centers, it is beyond the
scope of this study to correlate AV and VV delay optimization with
patient responsiveness to CRT therapy. This study was designed to
elucidate the trend for the overall use of certain methods for CRT
optimization. It is noteworthy that the method used during pre-
hospital discharge may differ from that used at each follow-up. To
further clarify the use of each method in correlation with patient
outcomes, a study with a much larger cohort is needed.5. Conclusions
A considerable proportion of Japanese physicians managing
CRT device recipients do not routinely optimize AV and/or VV
delay settings primarily owing to a lack of time and qualiﬁed staff.
Although echocardiography is commonly employed to optimize
AV and VV delays, the time and clinical resource burden associated
with this technique may prevent its routine use during CRT device
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